| AbbVie | Listed AbbVie brands incl. Humira, Skyrizi, Rinvoq; seven specialty-network brands | claims submission window, contract pharmacy limits, designation requirements | yes | Not stated | 45 days |
|---|
| Alkermes | Aristada, Aristada Initio, Lybalvi, Vivitrol | claims submission window, contract pharmacy limits, designation requirements | yes | 2025-12-01 | 45 days |
|---|
| Amgen | All products | claims submission window, contract pharmacy limits, designation requirements | yes | 2026-06-01 | 45 days |
|---|
| Amphastar | Baqsimi | claims submission window, contract pharmacy limits, designation requirements | yes | 2026-07-01 | 45 days |
|---|
| argenx | Vyvgart Hytrulo PFS | claims submission window, contract pharmacy limits, designation requirements | yes | 2025-11-14 | 45 days |
|---|
| Astellas | Xtandi, Myrbetriq, Cresemba, Xospata | designation requirements | no | 2025-10-01 | none stated |
|---|
| AstraZeneca | 19 retail + 5 specialty brands (ETCAMAH from 10-26-2026) | claims submission window, contract pharmacy limits, designation requirements | yes | 2026-10-26 | 45 days |
|---|
| Bausch + Lomb | Full ophthalmic/otic list incl. generics | claims submission window, contract pharmacy limits, designation requirements | yes | 2024-07-01 | none stated |
|---|
| Bayer | In-scope Bayer brands incl. Adempas, Nubeqa; Kerendia from 09-24-2026 | claims submission window, contract pharmacy limits, designation requirements | yes | 2024-10-01 | 45 days |
|---|
| Biogen | Tysabri added 11-23-2026. CP: Avonex/Plegridy/Zurzuvae. CLD: Avonex/Plegridy/Tecfidera/Vumerity. | claims submission window, contract pharmacy limits, designation requirements | yes | 2026-11-23 | 45 days |
|---|
| Boehringer Ingelheim | Exhibit A list (Jardiance, Spiriva, OFEV, etc.) | claims submission window, contract pharmacy limits, designation requirements | yes | 2024-12-02 | 45 days |
|---|
| Bristol Myers Squibb | 24 CLD products; IMiDs + specialty networks | claims submission window, contract pharmacy limits, designation requirements | yes | 2026-05-01 | 45 days |
|---|
| Cytokinetics | MYQORZO | claims submission window, contract pharmacy limits, designation requirements | no | 2026-08-03 | 45 days |
|---|
| Eisai | Aricept, Banzel, Dayvigo, Halaven, Lenvima, Leqembi | contract pharmacy limits, designation requirements | no | 2023-11-01 | none stated |
|---|
| Eli Lilly | All products (3 labeler codes) | claims submission window, contract pharmacy limits, designation requirements | yes | 2024-07-01 | 45 days |
|---|
| EMD Serono | All marketed products | contract pharmacy limits, designation requirements | yes | 2024-10-01 | none stated |
|---|
| Exelixis | Cometriq, Cabometyx | claims submission window, contract pharmacy limits, designation requirements | no | 2025-10-01 | 45 days |
|---|
| Genentech | All except Hemlibra, Evrysdi | claims submission window, contract pharmacy limits, designation requirements | yes | 2026-08-31 | 45 days |
|---|
| Gilead | Branded HCV (Epclusa, Harvoni, Sovaldi, Vosevi) | claims submission window, contract pharmacy limits, designation requirements | yes | 2026-06-15 | none stated |
|---|
| GSK | All PHS-contract products (excl. vaccines, ViiV) | claims submission window, contract pharmacy limits, designation requirements | yes | 2023-05-01 | 45 days |
|---|
| Incyte | Opzelura cream 1.5%; NDC 50881-0007-05 | contract pharmacy limits, designation requirements | no | 2023-10-16 | none stated |
|---|
| Jazz Pharmaceuticals | Epidiolex | contract pharmacy limits, designation requirements | no | 2026-05-15 | none stated |
|---|
| Johnson & Johnson (JJHCS) | J&J CODs; claims exclude miglustat (CoTherix), Vistaseal and Patriot drugs | claims submission window, contract pharmacy limits, designation requirements | yes | 2026-09-15 | 45 days |
|---|
| LEO Pharma | Adbry | claims submission window, contract pharmacy limits, designation requirements | no | 2026-06-22 | 45 days |
|---|
| Liquidia | Yutrepia | claims submission window, contract pharmacy limits, designation requirements | yes | 2026-06-11 | 45 days |
|---|
| Merck | 9 Table 1 brands, including Lipfendra from October 1; separate Winrevair CP terms | claims submission window, contract pharmacy limits, designation requirements | yes | 2026-10-01 | 45 days |
|---|
| Novartis | Listed products (per 340B ESP) | claims submission window, contract pharmacy limits, designation requirements | yes | 2025-01-01 | 45 days |
|---|
| Novo Nordisk | All products (3 labeler codes) | claims submission window, contract pharmacy limits, designation requirements | yes | 2026-04-01 | 45 days |
|---|
| Organon | All products (~95 NDCs) | claims submission window, contract pharmacy limits, designation requirements | yes | 2026-05-01 | 45 days |
|---|
| Pfizer | Exhibit A (~20 brands) + VYNDA + DON oncology | claims submission window, contract pharmacy limits, designation requirements | yes | 2026-03-31 | 45 days |
|---|
| Puma Biotechnology | All Puma NDCs (Nerlynx) | claims submission window, contract pharmacy limits, designation requirements | yes | 2026-01-01 | 45 days |
|---|
| Sandoz | Listed brands/biosimilars (incl. Tyruko, Ziextenzo, Cimerli) | claims submission window, contract pharmacy limits, designation requirements | no | 2026-02-01 | none stated |
|---|
| Sanofi | Attachment A products, including WAYRILZ (LDN); see archived NDC list | claims submission window, contract pharmacy limits, designation requirements | yes | 2026-06-15 | 45 days |
|---|
| Shionogi (formerly MTPA) | Radicava ORS | claims submission window, contract pharmacy limits, designation requirements | yes | 2026-04-01 | 45 days |
|---|
| Sobi | Doptelet, Kineret, Vonjo | claims submission window, contract pharmacy limits, designation requirements | yes | 2024-07-01 | 45 days |
|---|
| Stemline Therapeutics | Orserdu | claims submission window, contract pharmacy limits, designation requirements | yes | 2026-05-18 | 45 days |
|---|
| Sumitomo Pharma America (SMPA) | Aptiom, Gemtesa, Myfembree, Orgovyx | claims submission window, contract pharmacy limits, designation requirements | yes | 2026-06-11 | 45 days |
|---|
| Takeda | Retail brands incl. Mimrylo (08-28-2026); four LDN oncology brands | claims submission window, contract pharmacy limits, designation requirements | no | 2025-05-23 | 45 days |
|---|
| Teva | Attachment A (~40 brands) | claims submission window, contract pharmacy limits, designation requirements | no | 2023-07-05 | 45 days |
|---|
| UCB | Entire portfolio | claims submission window, contract pharmacy limits, designation requirements | yes | 2026-06-01 | 45 days |
|---|
| Vertex | All except Casgevy | claims submission window, designation requirements | no | 2025-02-04 | none stated |
|---|
| Viatris | Attachment A (EpiPen, Lyrica, Yupelri, etc.) | designation requirements | yes | 2024-08-01 | none stated |
|---|
